Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.

Clinica chimica acta; international journal of clinical chemistry - 12 May 2011

Kawashiri Masa-aki, Kobayashi Junji, Nohara Atsushi, Noguchi Tohru, Tada Hayato, Nakanishi Chiaki, Inazu Akihiro, Mabuchi Hiroshi, Yamagishi Masakazu

Abstract excerpt

BACKGROUND: We elucidated the difference between the effects of bezafibrate and atorvastatin in hypertriglyceridemia with apoE2/2 and 3/3. METHODS: An open randomized crossover study consisted of a 4-week treatment period with bezafibrate (400 mg daily) or atorvastatin (10 mg daily) and a 4-week wash-out period. RESULTS: Bezafibrate significantly decreased serum concentrations of triglyceride (apoE2/2, E3/3:...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoprotein E2
Share to Apolipoprotein E3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Atorvastatin

Share to Cross-Over Studies

Share to Heptanoic Acids

Share to Hyperlipoproteinemia Type III

Share to Hypolipidemic Agents

Share to Pyrroles

Source

Identifiers

PMID: 21354122
DOI: 10.1016/j.cca.2011.02.026

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of bezafibrate and atorvastatin on lipoprotein subclass in patients with type III hyperlipoproteinemia: result from a crossover study.PMID 21354122Read ↗

Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients.Semantic proximity Read ↗

Addressing dyslipidemic risk beyond LDL-cholesterol.Semantic proximity Read ↗

Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype.Semantic proximity Read ↗

Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults.Semantic proximity Read ↗

Effects of pravastatin on apolipoprotein-specific high density lipoprotein subpopulations and low density lipoprotein subclass phenotypes in patients with primary hypercholesterolemia.Semantic proximity Read ↗

Apolipoprotein C-III and the metabolic basis for hypertriglyceridemia and the dense low-density lipoprotein phenotype.Semantic proximity Read ↗

Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia.Semantic proximity Read ↗

Phenotype-dependent and -independent actions of rosuvastatin on atherogenic lipoprotein subfractions in hyperlipidaemia.Semantic proximity Read ↗

Effects of ezetimibe on lipids and lipoproteins in patients with hypercholesterolemia and different apolipoprotein E genotypes.Semantic proximity Read ↗

Additive Antiatherogenic Effects of CETP rs708272 on Serum LDL Subfraction Levels in Patients with CHD Under Statin Therapy.Semantic proximity Read ↗

Overview of fenofibrate.Semantic proximity Read ↗

CYP3AP1*3 allele is associated with lipid-lowering efficacy of simvastatin and atorvastatin in Chinese women.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.